LENZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
LENZ Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$3.30+0.03 (+0.92%)
Close on Oct 19, 2026
- Market cap
- $103.54M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
35M of 31M shares
Institutional holders
144
28 new, 27 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
6 buys · 2 sales
Net bought $393.83K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Rajeev Shah | 4,265,106 | 13.60% | 13D (active) amendment | Nov 5, 2025 |
| Lunate Holding RSC LTD | 3,612,211 | – | 13G (passive) | Mar 21, 2024 |
| Matthew Porteus | 3,548,529 | 6.10% | 13G (passive) amendment | Dec 31, 2023 |
| Tang Capital Partners, LP | 3,117,843 | 5.40% | 13G (passive) | Jan 24, 2024 |
| BlackRock, Inc. | 1,804,099 | 5.80% | 13G (passive) | Mar 31, 2026 |
| FMR LLC | 1,783,202 | 5.70% | 13G (passive) amendment | Aug 31, 2026 |
| Israel A. Englander | 1,603,512 | 5.10% | 13G (passive) | Jun 23, 2026 |
| Squarepoint (DIFC) Ltd | 1,593,246 | 5.10% | 13G (passive) | Apr 1, 2026 |
| Paradigm BioCapital Advisors LP | 1,419,832 | 5.20% | 13G (passive) | Mar 20, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of LENZ | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 4,178,823 | 13.30% | $23.74M | – | 0.21% |
| Alpha Wave Global, LP | 3,612,211 | 11.50% | $20.52M | – | 0.33% |
| FMR LLC | 3,558,905 | 11.33% | $20.21M | −38,879 | 0.00% |
| Versant Venture Management, LLC | 2,656,888 | 8.46% | $15.09M | – | 9.28% |
| BlackRock, Inc. | 2,292,121 | 7.30% | $13.02M | +315,298 | 0.00% |
| Squarepoint Ops LLC | 1,747,096 | 5.56% | $9.92M | +240,597 | 0.01% |
| abrdn plc | 1,547,883 | 4.93% | $8.79M | +391,722 | 0.01% |
| Millennium Management LLC | 1,508,478 | 4.80% | $8.57M | +639,221 | 0.00% |
| Vanguard Capital Management LLC | 1,097,755 | 3.49% | $6.24M | +56,567 | 0.00% |
| 72 Investment Holdings, LLC | 1,017,751 | 3.24% | $5.78M | – | 11.57% |
| Blue Owl Capital Holdings LP | 756,722 | 2.41% | $4.30M | +250,000 | 0.65% |
| C WorldWide Group Holding A/S | 700,000 | 2.23% | $3.98K | – | 0.10% |
| Geode Capital Management, LLC | 564,662 | 1.80% | $3.21M | +40,088 | 0.00% |
| Trexquant Investment LP | 497,526 | 1.58% | $2.83M | +283,118 | 0.02% |
| Marshall Wace, Llp | 493,099 | 1.57% | $2.80M | +332,835 | 0.00% |
| Qube Research & Technologies Ltd | 482,195 | 1.53% | $2.74M | New | 0.00% |
| Morgan Stanley | 472,995 | 1.51% | $2.69M | −175,853 | 0.00% |
| Primecap Management Co/Ca/ | 472,200 | 1.50% | $2.68M | – | 0.00% |
| Tang Capital Management LLC | 451,114 | 1.44% | $2.56M | – | 0.12% |
| Alyeska Investment Group, L.P. | 438,882 | 1.40% | $2.49M | −24,613 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 144 | 35M | 100.0% | 28 / 59 | 34 / 27 | 5M | 3M |
| Q1 2026 | 145 | 33M | 100.0% | 35 / 57 | 28 / 48 | 7M | 8M |
| Q4 2025 | 161 | 35M | 100.0% | 50 / 53 | 33 / 55 | 13M | 7M |
| Q3 2025 | 166 | 29M | 92.8% | 57 / 64 | 24 / 4 | 8M | 3M |
| Q2 2025 | 113 | 25M | 78.8% | 24 / 54 | 15 / 16 | 5M | 1M |
| Q1 2025 | 105 | 21M | 67.1% | 24 / 30 | 27 / 12 | 3M | 2M |
| Q4 2024 | 94 | 20M | 63.2% | 24 / 32 | 21 / 8 | 2M | 1M |
| Q3 2024 | 78 | 19M | 59.6% | 23 / 20 | 16 / 9 | 2M | 2M |
| Q2 2024 | 65 | 19M | 60.2% | 19 / 26 | 6 / 9 | 3M | 0M |
| Q1 2024 | 55 | 16M | 51.8% | 55 / 0 | 0 / 0 | 16M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of LENZ | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Growth Company Fund | 1,228,633 | 3.91% | $9.56M | 0.01% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 819,606 | 2.61% | $4.66M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 538,648 | 1.71% | $3.06M | 0.00% | Jun 30, 2026 |
| PRIMECAP Odyssey Aggressive Growth Fund | 406,400 | 1.29% | $2.15M | 0.03% | Jul 31, 2026 |
| Fidelity Series Growth Company Fund | 314,100 | 1.00% | $2.44M | 0.01% | May 31, 2026 |
| Fidelity Growth Company K6 Fund | 313,056 | 1.00% | $2.44M | 0.01% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 253,113 | 0.81% | $1.44M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 225,784 | 0.72% | $1.20M | 0.00% | Jul 31, 2026 |
| iShares Biotechnology ETF | 193,013 | 0.61% | $1.10M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 172,550 | 0.55% | $980.08K | 0.01% | Jun 30, 2026 |
| Schwab U.S. Small-Cap ETF | 104,012 | 0.33% | $809.21K | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 101,792 | 0.32% | $791.94K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 68,937 | 0.22% | $391.56K | 0.03% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 59,341 | 0.19% | $461.67K | 0.00% | May 31, 2026 |
| U.S. Small Cap Equity Fund | 56,217 | 0.18% | $297.95K | 0.03% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Evert B. Schimmelpennink | President, CEO and Secretary, Director | 77,289 | 0.25% | Mar 30, 2026 |
| Daniel R. Chevallard | Chief Financial Officer | 12,886 | 0.04% | Mar 30, 2026 |
| Marc Odrich | Chief Medical Officer | 99,599 | 0.32% | Jan 6, 2026 |
| Shawn Olsson | Chief Commercial Officer | 4,733 | 0.02% | Jan 6, 2026 |
| Shelley B. Thunen | Director | – | – | Jun 15, 2026 |
| Capital Healthcare Fund LP RA | Director, 10% owner | – | – | Jun 15, 2026 |
| Ra Capital Management, L.P. | Director, 10% owner | – | – | Jun 15, 2026 |
| Zachary Scheiner | Director | – | – | Jun 15, 2026 |
| RA Capital Nexus Fund II, L.P. | Director | 164,729 | 0.52% | Jun 15, 2026 |
| Frederic Guerard | Director | – | – | Jun 15, 2026 |
| Jeffrey P. George | Director | 5,592 | 0.02% | Jun 15, 2026 |
| Peter Kolchinsky | Director, 10% owner | – | – | Jun 15, 2026 |
| Kimberlee C. Drapkin | Director | – | – | Jun 15, 2026 |
| James W. McCollum | Director | 631,099 | 2.01% | Jun 15, 2026 |
| Rajeev M. Shah | Director, 10% owner | – | – | Jun 15, 2026 |
| Versant Ventures VII GP-GP, LLC | 10% owner | 2,623,811 | 8.35% | Oct 2, 2025 |
| Versant Venture Capital VI, L.P. | 10% owner | 2,916,537 | 9.28% | Oct 2, 2025 |
| Versant Ventures VI GP-GP, LLC | 10% owner | 2,364,671 | 7.53% | Oct 2, 2025 |
| Versant Ventures VI GP, L.P. | 10% owner | 3,015,187 | 9.60% | Oct 2, 2025 |
| Versant Vantage II, L.P. | 10% owner | – | – | Oct 2, 2025 |
| Versant Vantage II GP, L.P. | 10% owner | 4,542,150 | 14.46% | Oct 2, 2025 |
| Versant Vantage II GP-GP, LLC | 10% owner | 2,636,478 | 8.39% | Oct 2, 2025 |
| Versant Venture Capital VII, L.P. | 10% owner | 1,598,789 | 5.09% | Oct 2, 2025 |
| Versant Ventures VII GP, L.P. | 10% owner | 3,101,944 | 9.87% | Oct 2, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Evert B. Schimmelpennink President, CEO and Secretary, Director | Mar 27, 2026 | Buy | +28,089 | $8.95 | $251.40K | 77,289 |
| Daniel R. Chevallard Chief Financial Officer | Mar 27, 2026 | Buy | +7,500 | $8.57 | $64.28K | 12,886 |
| Jeffrey P. George Director | Mar 27, 2026 | Buy | +5,592 | $8.92 | $49.88K | 5,592 |
| Shawn Olsson Chief Commercial Officer | Nov 17, 2025 | Sale(10b5-1 plan) | −5,788 | $26.37 | $152.63K | 4,733 |
| Shawn Olsson Chief Commercial Officer | Nov 17, 2025 | Sale(10b5-1 plan) | −4,212 | $25.74 | $108.42K | 10,521 |
| Shawn Olsson Chief Commercial Officer | Nov 17, 2025 | Option exercise | +10,000 | $2.08 | $20.80K | 14,733 |
| James W. McCollum Director | Nov 7, 2025 | Buy | +10,500 | $22.79 | $239.30K | 10,500 |
| Daniel R. Chevallard Chief Financial Officer | Nov 7, 2025 | Buy | +20 | $22.71 | $454 | 3,208 |
| Daniel R. Chevallard Chief Financial Officer | Nov 7, 2025 | Buy | +2,178 | $22.76 | $49.57K | 5,386 |
| Versant Vantage II GP-GP, LLC 10% owner | Sep 30, 2025 | Sale | −123 | $47.01 | $5.78K | 764,127 |
| Versant Vantage II GP-GP, LLC 10% owner | Sep 30, 2025 | Sale | −177 | $47.01 | $8.32K | 1,050,599 |
| Versant Vantage II GP-GP, LLC 10% owner | Sep 30, 2025 | Sale | −57,502 | $46.41 | $2.67M | 764,250 |
| Versant Vantage II GP-GP, LLC 10% owner | Sep 30, 2025 | Sale | −83,066 | $46.41 | $3.86M | 1,050,776 |
| Versant Vantage II GP-GP, LLC 10% owner | Sep 30, 2025 | Sale | −49,701 | $45.35 | $2.25M | 1,133,842 |
| Versant Vantage II GP-GP, LLC 10% owner | Sep 30, 2025 | Sale | −34,405 | $45.35 | $1.56M | 821,752 |
| Versant Venture Capital VI, L.P. 10% owner | Sep 18, 2025 | Sale | −40,907 | $43.00 | $1.76M | 1,183,811 |
| Versant Venture Capital VI, L.P. 10% owner | Sep 18, 2025 | Sale | −268 | $43.30 | $11.60K | 1,183,543 |
| Versant Venture Capital VI, L.P. 10% owner | Sep 18, 2025 | Sale | −20,148 | $43.00 | $866.36K | 856,289 |
| Versant Venture Capital VI, L.P. 10% owner | Sep 18, 2025 | Sale | −132 | $43.30 | $5.72K | 856,157 |
| Versant Venture Capital VI, L.P. 10% owner | Sep 18, 2025 | Sale | −24,370 | $41.59 | $1.01M | 876,437 |
| Versant Venture Capital VI, L.P. 10% owner | Sep 18, 2025 | Sale | −49,479 | $41.59 | $2.06M | 1,224,718 |
| Versant Ventures VII GP, L.P. 10% owner | Aug 26, 2025 | Sale | −21,661 | $38.97 | $844.13K | 902,514 |
| Versant Ventures VII GP, L.P. 10% owner | Aug 26, 2025 | Sale | −3,465 | $39.50 | $136.87K | 1,274,197 |
| Versant Ventures VII GP, L.P. 10% owner | Aug 26, 2025 | Sale | −1,707 | $39.50 | $67.43K | 900,807 |
| Versant Ventures VII GP, L.P. 10% owner | Aug 26, 2025 | Sale | −43,978 | $38.97 | $1.71M | 1,277,662 |
| Versant Ventures VII GP, L.P. 10% owner | Aug 25, 2025 | Sale | −2,149 | $39.92 | $85.79K | 1,321,640 |
| Versant Ventures VII GP, L.P. 10% owner | Aug 25, 2025 | Sale | −24,760 | $39.53 | $978.76K | 925,233 |
| Versant Ventures VII GP, L.P. 10% owner | Aug 25, 2025 | Sale | −50,270 | $39.53 | $1.99M | 1,323,789 |
| Versant Ventures VII GP, L.P. 10% owner | Aug 25, 2025 | Sale | −1,058 | $39.92 | $42.24K | 924,175 |
| Versant Ventures VII GP, L.P. 10% owner | Aug 22, 2025 | Sale | −10,076 | $40.03 | $403.34K | 952,802 |
| Versant Ventures VII GP, L.P. 10% owner | Aug 22, 2025 | Sale | −2,809 | $40.59 | $114.02K | 949,993 |
| Versant Ventures VII GP, L.P. 10% owner | Aug 22, 2025 | Sale | −5,668 | $40.59 | $230.06K | 1,374,059 |
| Versant Ventures VII GP, L.P. 10% owner | Aug 22, 2025 | Sale | −20,493 | $40.03 | $820.33K | 1,379,727 |
| Versant Venture Capital VI, L.P. 10% owner | Aug 18, 2025 | Sale | −30,628 | $38.56 | $1.18M | 1,400,220 |
| Versant Venture Capital VI, L.P. 10% owner | Aug 18, 2025 | Sale | −15,085 | $38.56 | $581.68K | 962,878 |
| Versant Venture Capital VI, L.P. 10% owner | Aug 15, 2025 | Sale | −145,051 | $39.50 | $5.73M | 1,430,848 |
| Versant Venture Capital VI, L.P. 10% owner | Aug 15, 2025 | Sale | −69,949 | $39.50 | $2.76M | 977,963 |
| Versant Ventures VII GP-GP, LLC 10% owner | Jul 10, 2025 | Sale | −191,376 | $34.00 | $6.51M | 1,575,899 |
| Versant Vantage II GP-GP, LLC 10% owner | Jun 27, 2025 | Sale | −200,000 | $30.47 | $6.09M | 1,767,275 |
| Versant Ventures VI GP, L.P. 10% owner | Jun 20, 2025 | Sale | −133,924 | $30.25 | $4.05M | 1,967,275 |
| Versant Ventures VI GP, L.P. 10% owner | Jun 20, 2025 | Sale | −100,877 | $30.35 | $3.06M | 1,047,912 |
| Versant Ventures VI GP, L.P. 10% owner | Jun 18, 2025 | Sale | −100,000 | $29.95 | $3.00M | 1,148,789 |
| Versant Vantage II GP-GP, LLC 10% owner | Jun 10, 2025 | Sale | −350,000 | $29.00 | $10.15M | 1,248,789 |
| Shawn Olsson Chief Commercial Officer | Apr 9, 2025 | Option exercise | +1,400 | $2.08 | $2.91K | 4,733 |
| Evert B. Schimmelpennink President, CEO and Secretary, Director | Mar 7, 2025 | Option exercise | +4,200 | $1.04 | $4.37K | 49,200 |
| Shawn Olsson Chief Commercial Officer | Dec 16, 2024 | Option exercise | +3,333 | $2.08 | $6.93K | 3,333 |
| Evert B. Schimmelpennink President, CEO and Secretary, Director | Jul 22, 2024 | Option exercise | +45,000 | $1.04 | $46.80K | 45,000 |
| Daniel R. Chevallard Chief Financial Officer | May 14, 2024 | Buy | +3,188 | $15.68 | $49.99K | 3,188 |
| James W. McCollum Director | May 13, 2024 | Buy | +31,332 | $15.99 | $501.00K | 525,565 |
| James W. McCollum Director | Mar 21, 2024 | Award | +16,633 | $15.03 | $249.99K | 494,233 |
| James W. McCollum Director | Mar 21, 2024 | Award | +477,600 | – | – | 477,600 |
| James W. McCollum Director | Mar 21, 2024 | Award | +95,034 | – | – | 95,034 |
| Marc Odrich Chief Medical Officer | Mar 21, 2024 | Award | +99,599 | – | – | 99,599 |
| Versant Vantage II GP, L.P. 10% owner | Mar 21, 2024 | Other | +598,203 | – | – | 842,162 |
| RA Capital Nexus Fund II, L.P. Director, 10% owner | Mar 21, 2024 | Award | +164,729 | – | – | 164,729 |
| RA Capital Nexus Fund II, L.P. Director, 10% owner | Mar 21, 2024 | Award | +694,755 | – | – | 694,755 |
| RA Capital Nexus Fund II, L.P. Director, 10% owner | Mar 21, 2024 | Award | +2,386,301 | – | – | 2,386,301 |
| RA Capital Nexus Fund II, L.P. Director, 10% owner | Mar 21, 2024 | Buy | +933,038 | $15.03 | $14.02M | 3,319,339 |
| RA Capital Nexus Fund II, L.P. Director, 10% owner | Mar 21, 2024 | Buy | +64,971 | $15.03 | $976.51K | 694,755 |
| Srinivas Akkaraju 10% owner | Apr 12, 2022 | Buy | +350,000 | $4.08 | $1.43M | 8,459,314 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Olsson Shawn Officer | Nov 17, 2025 | 40,000 | $1.02M | Nov 17, 2025 | Exercise of Stock Options |